Rob S. Sellar

Rob S. Sellar

Auto-generated profile, based on publicly available information

Rob S. Sellar

UCL Cancer Institute and University College London Hospital, London, United Kingdom

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
OWOfir Wolach
Ofir Wolach
RSRob S. Sellar
Rob S. Sellar
KMKimberly Martinod
Kimberly Martinod
DCDeya Cherpokova
Deya Cherpokova
MMMarie McConkey
Marie McConkey
BEBenjamin L. Ebert
Benjamin L. Ebert
Thrombosis is a major cause of morbidity and mortality in Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), clonal disorders of hematopoiesis characterized by activated Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling. Neutrophil extracellular trap (NET) formation, a component of innate immunity, has been linked to thrombosis. We demonstrate that neutrophils from patients with MPNs are primed for NET formation, an effect blunted by pharmacological inhibition of JAK signaling. Mice with conditional knock-in of Jak2V617F, the most common molecular driver of MPN, have an increased propensity for NET formation and thrombosis. Inhibition of JAK-STAT signaling with the clinically available JAK2 inhibitor ruxolitinib abrogated NET formation and reduced thrombosis in a deep vein stenosis murine model. We further show that expression of PAD4, a protein required for NET formation, is increased in JAK2V617F-expressing neutrophils and that PAD4 is required for Jak2V617F-driven NET formation and thrombosis in vivo. Finally, in a population study of more than 10,000 individuals without a known myeloid disorder, JAK2V617F-positive clonal hematopoiesis was associated with an increased incidence of thrombosis. In aggregate, our results link JAK2V617F expression to NET formation and thrombosis and suggest that JAK2 inhibition may reduce thrombosis in MPNs through cell-intrinsic effects on neutrophil function.

16 November 2023 in Blood
Verified
Journal Article
Open access
PDF file
SFSylvie D. Freeman
Sylvie D. Freeman
ATAbin Thomas
Abin Thomas
ITIan Thomas
Ian Thomas
RHRobert K. Hills
Robert K. Hills
PVParesh Vyas
Paresh Vyas
NRNigel H. Russell
Nigel H. Russell
Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated schedule provides additional benefit to a single dose. We randomized 852 older adults (median age, 68-years) with AML/high-risk myelodysplasia to GO on day 1 (GO1) or on days 1 and 4 (GO2) of course 1 induction. The median follow-up period was 50.2 months. Although complete remission (CR) rates after course 1 did not significantly differ between arms (GO2, 63%; GO1, 57%; odds ratio [OR], 0.78; P = .08), there were significantly more patients who achieved CR with a measurable residual disease (MRD)<0.1% (50% vs 41%; OR, 0.72; P = .027). This differential MRD reduction with GO2 varied across molecular subtypes, being greatest for IDH mutations. The 5-year overall survival (OS) was 29% for patients in the GO2 arm and 24% for those in the GO1 arm (hazard ratio [HR], 0.89; P = .14). In a sensitivity analysis excluding patients found to have adverse cytogenetics or TP53 mutations, the 5-year OS was 33% for GO2 and 26% for GO1 (HR, 0.83; P = .045). In total, 228 (27%) patients received an allogeneic transplantation in first remission. Posttransplant OS was superior in the GO2 arm (HR, 0.67; P = .033); furthermore, the survival advantage from GO2 in the sensitivity analysis was lost when data of patients were censored at transplantation. In conclusion, GO2 was associated with a greater reduction in MRD and improved survival in older adults with nonadverse risk genetics. This benefit from GO2 was dependent on allogeneic transplantation to translate the better leukemia clearance into improved survival. This trial was registered at www.isrctn.com as #ISRCTN 31682779.

24 April 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RSRob S. Sellar
Rob S. Sellar
CRClare Rowntree
Clare Rowntree
AVAjay J. Vora
Ajay J. Vora
CFCaroline L. Furness
Caroline L. Furness
NGNicholas Goulden
Nicholas Goulden
RHRachael Hough
Rachael Hough

8 August 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
RSRob S. Sellar
Rob S. Sellar
VMVarun Mehra
Varun Mehra
TFThomas A. Fox
Thomas A. Fox
AGAndrew Grigg
Andrew Grigg
AKAustin Kulasekararaj
Austin Kulasekararaj
VPVictoria T. Potter
Victoria T. Potter
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.